Literature DB >> 1958262

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.

K A Jellinger1.   

Abstract

In Parkinson's disease (PD), in addition to degeneration of the nigrostriatal dopaminergic pathway, a variety of neuronal systems are involved, causing multiple neuromediator dysfunctions that account for the complex patterns of functional deficits. Degeneration affects the dopaminergic mesocorticolimbic system, the noradrenergic locus ceruleus (oral parts) and motor vagal nucleus, the serotonergic raphe nuclei, the cholinergic nucleus basalis of Meynert, pedunculopontine nucleus pars compacta, Westphal-Edinger nucleus, and many peptidergic brainstem nuclei. Cell losses in subcortical projection nuclei range from 30 to 90% of controls; they are more severe in depressed and demented PD patients. Most of the lesions are region-specific, affecting not all neurons containing a specific transmitter or harboring Lewy bodies. In contrast to Alzheimer's disease (AD), subcortical system lesions in Parkinson's disease appear not to be related to cortical pathology, suggesting independent or concomitant degeneration. The pathogenesis of multiple-system changes contributing to chemical pathology and clinical course of Parkinson's disease are unknown.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958262     DOI: 10.1007/bf03159935

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  126 in total

1.  Comparison of heart rate variability analysis methods in patients with Parkinson's disease.

Authors:  M Kallio; K Suominen; A M Bianchi; T Mäkikallio; T Haapaniemi; S Astafiev; K A Sotaniemi; V V Myllyä; U Tolonen
Journal:  Med Biol Eng Comput       Date:  2002-07       Impact factor: 2.602

2.  Illness comorbidity as a biomarker?

Authors:  Hymie Anisman; Shawn Hayley
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

3.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

4.  Amygdala pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl; K Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

5.  Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing.

Authors:  Y Abe; T Kachi; T Kato; Y Arahata; T Yamada; Y Washimi; K Iwai; K Ito; N Yanagisawa; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 6.  Pathophysiology of somatosensory abnormalities in Parkinson disease.

Authors:  Antonella Conte; Nashaba Khan; Giovanni Defazio; John C Rothwell; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

7.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

8.  Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.

Authors:  P O Fernagut; C B Hutson; S M Fleming; N A Tetreaut; J Salcedo; E Masliah; M F Chesselet
Journal:  Synapse       Date:  2007-12       Impact factor: 2.562

9.  Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients.

Authors:  Kelly A Mills; Zoltan Mari; Catherine Bakker; Vanessa Johnson; Gregory M Pontone; Alexander Pantelyat; Juan C Troncoso; Olga Pletnikova; Ted M Dawson; Liana S Rosenthal
Journal:  Parkinsonism Relat Disord       Date:  2016-09-25       Impact factor: 4.891

10.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.